Big data, small effects

Journal of Clinical Oncology

Volumn 34, Issue 11, 2016, Pages 1170-1171

  Hochster, Howard S ^a   Niedzwiecki, Donna ^b  

^a YALE CANCER CENTER   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE PLUS OXALIPLATIN; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ADJUVANT CHEMOTHERAPY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; COLON CANCER; COLON SURGERY; COMORBIDITY; DATA BASE; EDITORIAL; HUMAN; INTERNATIONAL COOPERATION; LYMPH NODE RATIO; NOMOGRAM; PRIORITY JOURNAL; RISK FACTOR; TREATMENT FAILURE; COLON TUMOR; FEMALE; MALE; MORTALITY; PATHOLOGY;

COLONIC NEOPLASMS; FEMALE; HUMANS; MALE; NOMOGRAMS;

EID: 84963736811     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.65.8161     Document Type: Editorial

References (7)

1. Cheung WY, Renfro LA, Kerr D, et al: Determinants of early mortality among 37, 568 patients with colon cancerwho participated in 25 clinical trials from the Adjuvant Colon Cancer End Points Database. J Clin Oncol 34:1182-1189, 2016.
2. Renfro LA, Shi Q, Sargent DJ: Mining the ACCENT database: A review and update. Chin Clin Oncol 2:18, 2013.
3. Sargent DJ, Wieand HS, Haller DG, et al: Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: Individual patient data from 20, 898 patients on 18 randomized trials. J Clin Oncol 23:8664-8670, 2005.
4. Gill S, Loprinzi CL, Sargent DJ, et al: Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: Who benefits and by how much? J Clin Oncol 22:1797-1806, 2004.
5. Sargent DJ, Goldberg RM, Jacobson SD, et al: A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 345: 1091-1097, 2001.
6. Andre T, Iveson T, Labianca R, et al: The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration: Prospective combined analysis of phase III trials investigating duration of adjuvant therapy with the FOLFOX (FOLFOX4 or modified FOLFOX6) or XELOX (3 versus 6 months) regimen for patients with stage III colon cancer: Trial design and current status. Curr Colorectal Cancer Rep 9:261-269, 2013.
7. Alberts SR, Sargent DJ, Nair S, et al: Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: A randomized trial. JAMA 307:1383-1393, 2012.